Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of alpelisib when given together
with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer
that has spread to other places in the body. Alpelisib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Androgen receptor can cause the growth
of breast cancer cells. Hormone therapy using enzalutamide may fight breast cancer by
lowering the amount of androgen the body makes. Giving alpelisib and enzalutamide may work
better in treating patients with breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Astellas Pharma Global Development, Inc. National Cancer Institute (NCI) Novartis